Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Moderna reports before market open, meaning Day 0 captures the first full trading session where the market reacts to results, and Day +1 reflects follow-through sentiment.

Historically, Moderna has been a volatile earnings mover, with an average absolute Day 0 move of 4.17% and an average Day 0 range of 9.24%. Day +1 follow-through has averaged 3.40% in absolute terms, with a range of 7.69%.

The most recent report (July 31, 2026) saw the stock decline 5.35% on Day 0 with an intraday range of 8.25%, followed by a modest +0.58% gain on Day +1. Prior to that, the May 1, 2026 report produced a small -1.24% Day 0 move but a strong +4.25% Day +1 rally, suggesting that initial reactions can be misleading and that investors often reassess after digesting management commentary.

The February 13, 2026 report delivered a +5.29% Day 0 pop and a +4.03% Day +1 gain, while the November 6, 2025 report saw a +3.27% Day 0 move and a +0.86% Day +1 follow-through. Earlier in 2025, the stock experienced sharper downside reactions, including a -6.61% Day 0 drop in August 2025 and a -6.86% Day +1 decline in November 2024.

The takeaway: Moderna's post-earnings price action is highly unpredictable, with both direction and magnitude varying widely. Investors should expect significant intraday volatility and be prepared for multi-day swings as the market digests not just the numbers, but also management's guidance and pipeline updates.

Part 2.2: Options Market Expected Move

The options market is pricing a 7.15% expected move for this earnings event, implying a range of $224.00 to $258.51. This is below the stock's historical average Day 0 range of 9.24%, suggesting that options traders may be underestimating potential volatility—or that the market has already priced in much of the uncertainty following the stock's massive year-to-date rally. Given Moderna's history of wide intraday swings and the high stakes around pipeline commentary, the actual move could exceed the options-implied range.

Part 3: What Analysts Are Saying

Analyst sentiment on Moderna is decidedly mixed. The stock carries an average recommendation of 3.00 (Hold), with 3 Strong Buys, 0 Moderate Buys, 17 Holds, 0 Moderate Sells, and 3 Strong Sells among the 23 analysts covering the company. This reflects a cautious consensus: while some see transformative potential in the cancer vaccine franchise, the majority are taking a wait-and-see approach.

The average price target of $140.28 implies downside of approximately 42% from the current price of $241.21, a striking disconnect that underscores the market's aggressive pricing of future pipeline success. The range of targets is wide, spanning from a low of $45.00 to a high of $250.00, illustrating deep disagreement about the company's long-term value.

Sentiment has deteriorated over the past month, with the average recommendation slipping from 3.09 to 3.00. The number of Strong Buys declined from 4 to 3, while Holds increased from 16 to 17, suggesting that some analysts are growing more cautious as the stock has rallied and valuation has stretched.

The consensus view appears to be that Moderna's pipeline—particularly intismeran—holds significant promise, but the path to commercialization is long, execution risks remain high, and the current valuation leaves little margin for error. Analysts are effectively telling investors that the stock has run ahead of fundamentals, and that a more attractive entry point may emerge if near-term results or guidance disappoint.

Part 4: Technical Picture

Moderna is entering earnings with strong technical momentum. The stock is trading above all key moving averages: 7 days above the 5-day MA ($234.12), 20 points above the 10-day MA ($221.44), 18 points above the 20-day MA ($223.38), 52 points above the 50-day MA ($189.61), 110 points above the 100-day MA ($131.57), and 151 points above the 200-day MA ($90.45). This configuration signals a powerful uptrend across all timeframes.

The Barchart Technical Opinion currently stands at 100% Buy, unchanged from last week and last month, reflecting maximum bullish conviction from the technical model.

Timeframe Analysis:

• Short-term (100% Buy): Maximum buy signal indicates near-term momentum is exceptionally strong, with the stock in a steep uptrend
• Medium-term (100% Buy): Continued strength in the intermediate timeframe suggests the rally has legs and is not just a short-term spike
• Long-term (100% Buy): The long-term trend is also fully bullish, indicating that the stock has broken out of its prior downtrend and established a new structural uptrend

Trend Characteristics: The signal strength is at Maximum and the direction is Strongest, indicating that Moderna is in an exceptionally powerful uptrend with broad-based momentum across all timeframes—a rare technical setup that suggests strong underlying buying pressure heading into the earnings event.

The technical picture is unambiguously bullish, with the stock riding a steep uptrend and trading well above all major moving averages. The 50-day MA at $189.61 has provided strong support during recent pullbacks, and the stock's ability to hold above the shorter-term averages suggests that buyers remain in control.

However, the maximum bullish signal also means the stock is technically overbought, and any disappointment in earnings or guidance could trigger a sharp reversal. The wide gap between the current price and the 200-day MA ($90.45) highlights how far and how fast the stock has run—a setup that can amplify downside volatility if sentiment shifts. For traders, the technical setup is supportive heading into earnings, but the risk of a "sell the news" reaction is elevated given the magnitude of the year-to-date rally and the stretched valuation backdrop.